Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03303495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

StatusRecruiting
PhasePhase 3
Started2011-11-14
View on ClinicalTrials.gov ↗

Amendment history

2026-06-03
Study Status, Sponsor/Collaborators, Study Description, Outcome Measures v1
Primary completion date2017-12-31→2026-12-31
Completion date2018-12-31→2026-12-31
Secondary endpoints5 entries, revised
Progression-freeOverall survival (PFS)
Primary endpoints1 entry, revised
OverallProgression-free survival (PFS)
Study description+1 characters
Primary endpoint: Overall survival (OS), Secondary endpoints: Progression-free survival (PFS)； Secondary endpoints: Overall survival (OS), Time to treatment failure (TTF), Overall response rate (ORR), Disease Control Rate (DCR), Safety.
2017-10-02
Original filing
The primary purpose of this study is to determine the non-inferiority of overall survival FOLFIRI with or without Bevacizumab compared with Irinotecan (CPT-11) with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.
Trial Details
NCT Number NCT03303495
Lead Sponsor Sun Yat-sen University
Conditions Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
Enrollment 280 participants
Start Date 2011-11-14
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05